Semaglutide + Firsocostat + Cilofexor
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Jul 29, 2019 → Jul 13, 2020
NCT ID
NCT03987074About Semaglutide + Firsocostat + Cilofexor
Semaglutide + Firsocostat + Cilofexor is a phase 2 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03987074. Target conditions include Nonalcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03987074 | Phase 2 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis